Isn't it fundamentally obvious? The main thrust of MSB was always to treat ARDS, never COVID-19 itself. The virus doesn't kill people, the over-reaction of the body's immune system does. Remestemcel-L was always aimed at treating the cyctokine storms and related over inflammatory reaction that COVID-19 encourages in some people. SI couldn't have been any clearer.
He is being realistic. Anyway, if a vaccine emerges it will not be foolproof. Flu vaccines run at about 50-70% effectiveness. Coronavirus vaccines have never been successfully produced. Even if one is there are still going to be plenty of ARDS cases before and even after a vaccine is produced. 40% of flu deaths (and they can still approach 1 million globally) are from ARDS. Many deaths from Sepsis from ARDS. ARDS will continue to be a huge issue even if a vaccine for COVID-19 is produced.
MSB is going to be the gold star treatment for the worse effects of COVID-19, not addressing COVID-19 directly. That is huge in the battle against this pandemic. Hopefully the powers that be catch on and Remestemcel-L is taken quickly so hundreds of thousands need not die before a vaccine comes to fruition.
Forbes online interview, page-14
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.31 |
Change
0.040(3.16%) |
Mkt cap ! $1.490B | |||
| Open | High | Low | Value | Volume |
| $1.28 | $1.32 | $1.26 | $3.433M | 2.652M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 39558 | $1.30 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.31 | 21776 | 3 |
View Market Depth
| Last trade - 16.10pm 28/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |